Matchpoint nets $150M series B to take covalent med into clinic
Matchpoint Therapeutics raised a $150M Series B to take its covalent medicine into the clinic.
Matchpoint Therapeutics
Private
Biotechnology company discovering and developing precision small-molecule medicines that harness covalency to treat serious immune disease and cancer.
Company Info
Sector:Small Molecule Drug Discovery / Immunology
Headquarters:Watertown, Massachusetts, United States
Founded:2022
Website:matchpointtx.com/
Funding Round:Series B
Total Funding:$250M (Series A $100M + Series B $150M)
Funding & Investor Relations
IPO Outlook / Plans
Private; no IPO announced